203 related articles for article (PubMed ID: 26464264)
21. Cyclin-dependent kinase 5 phosphorylates endothelial nitric oxide synthase at serine 116.
Cho DH; Seo J; Park JH; Jo C; Choi YJ; Soh JW; Jo I
Hypertension; 2010 Feb; 55(2):345-52. PubMed ID: 20048197
[TBL] [Abstract][Full Text] [Related]
22. Structure, regulation, and (patho-)physiological functions of the stress-induced protein kinase CK1 delta (CSNK1D).
Xu P; Ianes C; Gärtner F; Liu C; Burster T; Bakulev V; Rachidi N; Knippschild U; Bischof J
Gene; 2019 Oct; 715():144005. PubMed ID: 31376410
[TBL] [Abstract][Full Text] [Related]
23. Transforming growth factor-β1 induces cell cycle arrest by activating atypical cyclin-dependent kinase 5 through up-regulation of Smad3-dependent p35 expression in human MCF10A mammary epithelial cells.
Park SJ; Yang SW; Kim BC
Biochem Biophys Res Commun; 2016 Apr; 472(3):502-7. PubMed ID: 26966064
[TBL] [Abstract][Full Text] [Related]
24. Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma.
Abdullah C; Wang X; Becker D
Cell Cycle; 2011 Mar; 10(6):977-88. PubMed ID: 21358262
[TBL] [Abstract][Full Text] [Related]
25. Cyclin-dependent kinase 5 modulates STAT3 and androgen receptor activation through phosphorylation of Ser⁷²⁷ on STAT3 in prostate cancer cells.
Hsu FN; Chen MC; Lin KC; Peng YT; Li PC; Lin E; Chiang MC; Hsieh JT; Lin H
Am J Physiol Endocrinol Metab; 2013 Oct; 305(8):E975-86. PubMed ID: 23941877
[TBL] [Abstract][Full Text] [Related]
26. Regulation of membrane association and kinase activity of Cdk5-p35 by phosphorylation of p35.
Sato K; Zhu YS; Saito T; Yotsumoto K; Asada A; Hasegawa M; Hisanaga S
J Neurosci Res; 2007 Nov; 85(14):3071-8. PubMed ID: 17671990
[TBL] [Abstract][Full Text] [Related]
27. The p35/Cdk5 kinase is a neuron-specific Rac effector that inhibits Pak1 activity.
Nikolic M; Chou MM; Lu W; Mayer BJ; Tsai LH
Nature; 1998 Sep; 395(6698):194-8. PubMed ID: 9744280
[TBL] [Abstract][Full Text] [Related]
28. Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models.
Hu C; Dadon T; Chenna V; Yabuuchi S; Bannerji R; Booher R; Strack P; Azad N; Nelkin BD; Maitra A
Mol Cancer Ther; 2015 Jul; 14(7):1532-9. PubMed ID: 25931518
[TBL] [Abstract][Full Text] [Related]
29. The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling.
Desai BM; Villanueva J; Nguyen TT; Lioni M; Xiao M; Kong J; Krepler C; Vultur A; Flaherty KT; Nathanson KL; Smalley KS; Herlyn M
PLoS One; 2013; 8(3):e59588. PubMed ID: 23527225
[TBL] [Abstract][Full Text] [Related]
30. Relationship between a point mutation S97C in CK1δ protein and its affect on ATP-binding affinity.
Kumar A; Rajendran V; Sethumadhavan R; Purohit R
J Biomol Struct Dyn; 2014; 32(3):394-405. PubMed ID: 23527964
[TBL] [Abstract][Full Text] [Related]
31. The regulation of SIRT2 function by cyclin-dependent kinases affects cell motility.
Pandithage R; Lilischkis R; Harting K; Wolf A; Jedamzik B; Lüscher-Firzlaff J; Vervoorts J; Lasonder E; Kremmer E; Knöll B; Lüscher B
J Cell Biol; 2008 Mar; 180(5):915-29. PubMed ID: 18332217
[TBL] [Abstract][Full Text] [Related]
32. Phosphorylation of p35 and p39 by Cdk5 determines the subcellular location of the holokinase in a phosphorylation-site-specific manner.
Asada A; Saito T; Hisanaga S
J Cell Sci; 2012 Jul; 125(Pt 14):3421-9. PubMed ID: 22467861
[TBL] [Abstract][Full Text] [Related]
33. Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9.
Saqub H; Proetsch-Gugerbauer H; Bezrookove V; Nosrati M; Vaquero EM; de Semir D; Ice RJ; McAllister S; Soroceanu L; Kashani-Sabet M; Osorio R; Dar AA
Sci Rep; 2020 Oct; 10(1):18489. PubMed ID: 33116269
[TBL] [Abstract][Full Text] [Related]
34. Glucose-induced expression of the cyclin-dependent protein kinase 5 activator p35 involved in Alzheimer's disease regulates insulin gene transcription in pancreatic beta-cells.
Ubeda M; Kemp DM; Habener JF
Endocrinology; 2004 Jun; 145(6):3023-31. PubMed ID: 14976144
[TBL] [Abstract][Full Text] [Related]
35. Induction of cyclin-dependent kinase 5 and its activator p35 through the extracellular-signal-regulated kinase and protein kinase A pathways during retinoic-acid mediated neuronal differentiation in human neuroblastoma SK-N-BE(2)C cells.
Lee JH; Kim KT
J Neurochem; 2004 Nov; 91(3):634-47. PubMed ID: 15485494
[TBL] [Abstract][Full Text] [Related]
36. Neuronal cyclin-dependent kinase 5: role in nervous system function and its specific inhibition by the Cdk5 inhibitory peptide.
Kesavapany S; Li BS; Amin N; Zheng YL; Grant P; Pant HC
Biochim Biophys Acta; 2004 Mar; 1697(1-2):143-53. PubMed ID: 15023357
[TBL] [Abstract][Full Text] [Related]
37. Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity.
Chen Z; Wang Z; Pang JC; Yu Y; Bieerkehazhi S; Lu J; Hu T; Zhao Y; Xu X; Zhang H; Yi JS; Liu S; Yang J
Sci Rep; 2016 Jul; 6():29090. PubMed ID: 27378523
[TBL] [Abstract][Full Text] [Related]
38. Optimized 4,5-Diarylimidazoles as Potent/Selective Inhibitors of Protein Kinase CK1δ and Their Structural Relation to p38α MAPK.
Halekotte J; Witt L; Ianes C; Krüger M; Bührmann M; Rauh D; Pichlo C; Brunstein E; Luxenburger A; Baumann U; Knippschild U; Bischof J; Peifer C
Molecules; 2017 Mar; 22(4):. PubMed ID: 28338621
[TBL] [Abstract][Full Text] [Related]
39. Casein Kinase 1δ Inhibitors as Promising Therapeutic Agents for Neurodegenerative Disorders.
Catarzi D; Varano F; Vigiani E; Lambertucci C; Spinaci A; Volpini R; Colotta V
Curr Med Chem; 2022; 29(27):4698-4737. PubMed ID: 35232339
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of gamma-secretase by the CK1 inhibitor IC261 does not depend on CK1delta.
Höttecke N; Liebeck M; Baumann K; Schubenel R; Winkler E; Steiner H; Schmidt B
Bioorg Med Chem Lett; 2010 May; 20(9):2958-63. PubMed ID: 20350806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
